^
    Apply
    To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (NCT05365178)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Active, not recruiting
    Last update posted :
    12/29/2023
    Initiation :
    07/01/2022
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    HER-2
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    fulvestrant • culmerciclib (TQB3616)
    Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer (NCT05780567)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    04/21/2023
    Initiation :
    03/30/2023
    Primary completion :
    12/01/2026
    Completion :
    01/01/2027
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • culmerciclib (TQB3616)
    TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail (NCT05375461)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    05/16/2022
    Initiation :
    03/18/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors (NCT05139082)
    Phase 1/2
    Peking University
    Not yet recruiting
    Last update posted :
    12/01/2021
    Initiation :
    11/24/2021
    Primary completion :
    10/01/2023
    Completion :
    10/01/2023
    PD-L1
    |
    Andewei (benmelstobart) • culmerciclib (TQB3616)
    A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer (NCT04796623)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    03/15/2021
    Initiation :
    02/04/2021
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer (TQB3616-II-01) (NCT04773418)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    02/26/2021
    Initiation :
    02/04/2021
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (NCT03850873)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    02/22/2019
    Initiation :
    03/01/2019
    Primary completion :
    09/30/2020
    Completion :
    09/30/2021
    HER-2 • ER
    |
    culmerciclib (TQB3616)